CL2021002169A1 - Métodos para obtener células de músculo liso inducidas - Google Patents

Métodos para obtener células de músculo liso inducidas

Info

Publication number
CL2021002169A1
CL2021002169A1 CL2021002169A CL2021002169A CL2021002169A1 CL 2021002169 A1 CL2021002169 A1 CL 2021002169A1 CL 2021002169 A CL2021002169 A CL 2021002169A CL 2021002169 A CL2021002169 A CL 2021002169A CL 2021002169 A1 CL2021002169 A1 CL 2021002169A1
Authority
CL
Chile
Prior art keywords
methods
smooth muscle
muscle cells
induced smooth
ismc
Prior art date
Application number
CL2021002169A
Other languages
English (en)
Spanish (es)
Inventor
Marco Thurner
Rainer Marksteiner
Original Assignee
Innovacell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovacell Ag filed Critical Innovacell Ag
Publication of CL2021002169A1 publication Critical patent/CL2021002169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0661—Smooth muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CL2021002169A 2019-03-22 2021-08-16 Métodos para obtener células de músculo liso inducidas CL2021002169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19164574 2019-03-22

Publications (1)

Publication Number Publication Date
CL2021002169A1 true CL2021002169A1 (es) 2022-02-25

Family

ID=65904308

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002169A CL2021002169A1 (es) 2019-03-22 2021-08-16 Métodos para obtener células de músculo liso inducidas

Country Status (14)

Country Link
US (2) US12312600B2 (enExample)
EP (2) EP4397752A3 (enExample)
JP (2) JP7616665B2 (enExample)
KR (1) KR20220002315A (enExample)
CN (2) CN113614223B (enExample)
AU (1) AU2020247211B2 (enExample)
BR (1) BR112021016264A2 (enExample)
CL (1) CL2021002169A1 (enExample)
DK (1) DK3942020T3 (enExample)
ES (1) ES2987152T3 (enExample)
IL (1) IL286509B2 (enExample)
MX (1) MX2021009862A (enExample)
WO (1) WO2020193460A1 (enExample)
ZA (1) ZA202104948B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102780297B1 (ko) 2017-12-14 2025-03-12 이노바셀 바이오테크놀로지 아게 근육 유래 세포를 수득하는 방법
KR20220002315A (ko) 2019-03-22 2022-01-06 이노바셀 아게 유도된 평활근 세포를 수득하는 방법
EP4741009A3 (en) 2021-08-06 2026-08-12 Innovacell GmbH Myogenic progenitor cells for use in an optimized method for the prevention and treatment of anal incontinence

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US8211423B2 (en) * 2006-11-28 2012-07-03 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US6555374B1 (en) * 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
AU5159901A (en) 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
JPWO2003027281A1 (ja) 2001-09-20 2005-01-06 協和醗酵工業株式会社 骨格筋間質由来多分化能幹細胞
ATE482713T1 (de) 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
WO2007010858A1 (ja) * 2005-07-15 2007-01-25 Kyoto University 骨格筋組織由来の単一細胞よりクローン化した多能性幹細胞
FR2890977A1 (fr) 2005-09-19 2007-03-23 Assist Publ Hopitaux De Paris Procede d'obtention de cellules musculaires lisses humaines et leurs applications
US20100273231A1 (en) * 2005-09-20 2010-10-28 Andreadis Stelios T Multipotent mesenchymal stem cells from human hair follicles
WO2007106200A2 (en) 2006-01-10 2007-09-20 Theradigm, Inc. Expansion and differentiation of neural stem cells under low oxygen conditions
US20080208164A1 (en) 2007-02-28 2008-08-28 Innovacell Biotechnologie Gmbh Methods for the treatment of anal incontinence
US20090155221A1 (en) 2007-05-29 2009-06-18 Thomas Payne Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
EP2206774A1 (en) 2008-12-23 2010-07-14 Genzyme Corporation Muscle-derived cells having differentiation capacities
US20140030236A1 (en) * 2010-02-25 2014-01-30 The Johns Hopkins University Derivation and maturation of synthetic and contractile vascular smooth muscle cells from human pluripotent stem cells
CN106267352A (zh) * 2010-05-03 2017-01-04 再生医学（开曼）有限公司 平滑肌细胞结构
WO2014039654A1 (en) * 2012-09-06 2014-03-13 Joslin Diabetes Center, Inc. Isolation and characterization of muscle regenerating cells
WO2014044867A1 (en) * 2012-09-24 2014-03-27 Innovacell Biotechnologie Ag Potency assay for skeletal muscle derived cells
EP3056562A1 (en) * 2015-02-11 2016-08-17 University College Cork-National University of Ireland, Cork Induced smooth muscle-type cells, methods for the production thereof, and uses thereof in cell-based tissue regeneration and treatment of vascular occlusion
CN106350480B (zh) 2016-08-26 2019-11-08 中国农业科学院北京畜牧兽医研究所 一种纯化牛胎儿骨骼肌组织来源成肌细胞的方法
KR102780297B1 (ko) 2017-12-14 2025-03-12 이노바셀 바이오테크놀로지 아게 근육 유래 세포를 수득하는 방법
KR20220002315A (ko) 2019-03-22 2022-01-06 이노바셀 아게 유도된 평활근 세포를 수득하는 방법
EP4741009A3 (en) 2021-08-06 2026-08-12 Innovacell GmbH Myogenic progenitor cells for use in an optimized method for the prevention and treatment of anal incontinence

Also Published As

Publication number Publication date
WO2020193460A1 (en) 2020-10-01
JP2025011242A (ja) 2025-01-23
CN113614223B (zh) 2025-05-27
IL286509A (en) 2021-10-31
JP7616665B2 (ja) 2025-01-17
IL286509B1 (en) 2026-04-01
US20220145257A1 (en) 2022-05-12
DK3942020T3 (da) 2024-07-15
CN113614223A (zh) 2021-11-05
JP2022526229A (ja) 2022-05-24
EP4397752A3 (en) 2024-10-02
AU2020247211B2 (en) 2024-07-04
US20250207097A1 (en) 2025-06-26
EP3942020B1 (en) 2024-05-15
MX2021009862A (es) 2021-09-14
NZ778000A (en) 2025-07-25
CN120738111A (zh) 2025-10-03
KR20220002315A (ko) 2022-01-06
CA3134213A1 (en) 2020-10-01
ZA202104948B (en) 2024-08-28
BR112021016264A2 (pt) 2021-10-13
US12312600B2 (en) 2025-05-27
AU2020247211A1 (en) 2021-07-29
IL286509B2 (en) 2026-08-01
EP3942020A1 (en) 2022-01-26
ES2987152T3 (es) 2024-11-14
EP4397752A2 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
SA521422089B1 (ar) c أجسام مضادة مكتسبة للسمة البشرية ضد مجموعة
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
CL2019002897A1 (es) Tratamiento para el asma con anticuerpo anti-tslp.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
MX2017002750A (es) Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
MX2018007089A (es) Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
ES2692773T3 (es) Tratamientos para la fibrosis
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
TR201909420T4 (tr) Bağ veya tendonun onarımına yönelik yöntem.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
CO7240399A2 (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos
MX2020003901A (es) Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
CL2020001480A1 (es) Métodos para obtener células derivadas de músculo.
CL2018003167A1 (es) Selección de cepas bacterianas útiles en el tratamiento de alergias.
CL2021001554A1 (es) Métodos para el tratamiento de discinesia en parálisis cerebral.